A comprehensive study highlighted that pregnant women with COVID-19 have a lower incidence of post-acute sequelae compared to non-pregnant women, emphasizing the need for tailored clinical care.
“Early in the pandemic, clinical care and research efforts focused on prevention of the acute morbidity and mortality caused by SARS-CoV-2 infection. Over time, the lasting health implications of COVID-19 have become increasingly pressing with an ongoing need for further evidence to inform clinical care. Studies have consistently identified a host of symptoms described in nearly every organ system in the months following SARS-CoV-2 infection,” according to the investigators.
The study, encompassing 83,915 non-pregnant females with SARS-CoV-2 infection acquired outside of pregnancy and 5,397 pregnant females with SARS-CoV-2 infection, highlights intriguing disparities. Notably, pregnant individuals who contracted the virus exhibited a lower incidence of PASC (25.5% vs. 33.9%; adjusted hazard ratio (aHR) 0.85, 95% confidence interval (CI) 0.80–0.91) compared to their non-pregnant counterparts.
The analysis also revealed an increased risk of specific PASC component diagnoses among pregnant individuals, such as abnormal heartbeat (aHR 1.67, 95% CI 1.43–1.94), abdominal pain (aHR 1.34, 95% CI 1.16–1.55), and thromboembolism (aHR 1.88, 95% CI 1.17–3.04). Conversely, pregnant individuals exhibited a decreased risk of other diagnoses, including malaise (aHR 0.35, 95% CI 0.27–0.47), pharyngitis (aHR 0.36, 95% CI 0.26–0.48), and cognitive problems (aHR 0.39, 95% CI 0.27–0.56).
Investigators compare this trial to another back in 2020, “in a retrospective cohort study of 14,104 individuals delivering across 17 US hospitals in 2020, those with SARS-CoV-2 infection were more likely to experience maternal mortality or severe morbidity from postpartum hemorrhage, infection, or hypertensive disorders of pregnancy than those without SARS-CoV-2 infection (13.4% vs 9.2%; aRR 1.41, 95% CI 1.23–1.61). SARS-CoV-2 infection in pregnancy has also been associated with increased risk for intensive care unit admission, need for mechanical ventilation, and cardiovascular complications among other acute sequelae.”
This retrospective cohort study, conducted as part of the Researching COVID to Enhance Recovery (RECOVER) Initiative Patient-Centered Clinical Research Network (PCORnet), leveraged electronic health record (EHR) data from 19 US health systems. Focusing on females aged 18–49 years with lab-confirmed SARS-CoV-2 infection between March 2020 and June 2022, the study identified pregnancies with deliveries at >20 weeks’ gestation. The primary outcome assessed was PASC identified 30–180 days post-SARS-CoV-2 infection.
“We evaluated PASC in individuals acquiring SARS-CoV-2 infection during pregnancy, which has not previously been reported,” according to investigators. “The selected PCORnet EHR-based study cohort reflects the geographic and racial diversity of the US increasing generalizability of the findings. A data-driven analysis approach using inverse probability of treatment weighting allowed for robust modeling and adjustment for confounders.”
Despite the study's strengths, including its use of a diverse and geographically representative cohort, certain limitations include potential biases such as misclassification, and under-ascertainment due to the reliance on ICD-10 codes in EHR datasets. Additionally, exclusions based on gestational age and data collection limitations may impact the findings' generalizability.
In conclusion, the study indicates that acquiring SARS-CoV-2 infection during pregnancy is associated with a lower incidence of PASC than acquiring the infection outside of pregnancy, within 30–180 days post-infection. These findings emphasize the need for tailored care for pregnant patients post-COVID-19 infection. Integrating these findings into clinical practice can improve care for pregnant patients post-COVID-19.
This article was published by our sister publication Contagion Live.
Reference
Bruno A, Zang C, Xu Z, et. al. Association between acquiring SARS-CoV-2 during pregnancy and post-acute sequelae of SARS-CoV-2 infection: RECOVER electronic health record cohort analysis. TheLancet. 2024. doi:10.1016/j.eclinm.2024.102654
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Expert consensus sheds light on diagnosis and management of vasa previa
December 5th 2024A recent review established guidelines for prenatal diagnosis and care of vasa previa, outlining its definition, screening and diagnosis, management, and timing of delivery in asymptomatic patients.
Read More
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
Cesarean delivery reduces mortality risk in preterm breech births
December 2nd 2024In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.
Read More
Reduced subsequent births reported after severe maternal morbidity
November 26th 2024Women experiencing severe maternal morbidity during their first pregnancy face significantly lower odds of subsequent births, emphasizing the need for personalized reproductive counseling and ongoing monitoring.
Read More